Rhythm Pharmaceuticals Inc — Balance Sheet (NASDAQ:RYTM) | MetaTrader

Open full chart

Financials

Overview Relevé Statistics Dividends

Quarterly Annual

Total assets 187.07 M329.52 M382.48 M332.75 M392.27 M480.2 M Total liabilities 20.55 M45.37 M118.22 M162.99 M227.72 M210.17 M Total equity 166.53 M284.15 M264.26 M169.76 M21.73 M139.07 M Total liabilities & shareholders' equities 187.07 M329.52 M382.48 M332.75 M392.27 M480.2 M Total debt —————— Net debt ——————

Nouvelles

Guggenheim raises Rhythm Pharmaceuticals stock price target on guidance

Citizens relève l’objectif de cours de Rhythm Pharmaceuticals sur fond d’approbation HO

Citizens raises Rhythm Pharmaceuticals stock price target on HO approval outlook

Stifel réitère son conseil d’Achat sur Rhythm Pharmaceuticals, objectif 131$

Stifel reiterates Buy on Rhythm Pharmaceuticals stock, $131 target

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Beats Revenue Estimates

Rhythm Pharma T4 2025 : revenus supérieurs aux attentes avant le lancement HO

Rhythm Pharma Q4 2025 slides: revenue beats as HO launch nears

Le BPA de Rhythm Pharma a dépassé les attentes de 0,09$, le CA a surpassé les prévisions

Rhythm Pharma earnings beat by $0.09, revenue topped estimates

Rhythm Pharmaceuticals est bien positionné, selon un analyste, et pourrait capturer une grande part du marché de l'obésité rare | Benzinga France

Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: Should You Buy?